SELL and metabolic dysfunction-associated steatohepatitis: We thereby demonstrate that CD62L expression is altered in human NAFLD/NASH and that deletion and therapeutic blockade of CD62L in mice prevents development and progression of steatohepatitis by mediating immune cell infiltration and thereby reducing the hepatic oxidative stress environment.